CytomX Therapeutics
CTMX
119 hedge funds and large institutions have $637M invested in CytomX Therapeutics in 2017 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 24 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
96% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 24
45% more capital invested
Capital invested by funds: $441M → $637M (+$196M)
23% more funds holding
Funds holding: 97 → 119 (+22)
12.74% more ownership
Funds ownership: 65.75% → 78.49% (+13%)
58% less call options, than puts
Call options by funds: $21K | Put options by funds: $50K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$22.8M |
| 2 |
BlackRock
New York
|
+$12.2M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$12.2M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$7.86M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.93M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$22.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.1M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$8.18M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.5M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.63M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
126
Virtu Financial
New York
| – | -$223K | -12,291 | Closed |
|
|
DCM
127
DAFNA Capital Management
Los Angeles,
California
| – | -$107K | -5,900 | Closed |
|
128
Acadian Asset Management
Boston,
Massachusetts
| – | -$29K | -1,608 | Closed |
|
|
TRCT
129
Tower Research Capital (TRC)
New York
| – | -$28K | -1,508 | Closed |
|
130
Simplex Trading
Chicago,
Illinois
| – | -$5K | -290 | Closed |
|
|
TWA
131
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2K | -100 | Closed |
|
CTMX Hedge Fund Activity: Q4 2017 in Review
119 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q4 2017, worth a combined $637M — up 45% from $441M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CTMX positions and 12 closed out — a net gain of 22 holders — while 47 added to existing stakes and 24 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $22.8M. The largest seller was BVF Inc, cutting an estimated $22.9M.
- 119 institutional investors held CytomX Therapeutics (CTMX) as of Q4 2017, up from 97 in Q3 2017.
- Funds reported $637M of CytomX Therapeutics stock for Q4 2017, up 45% quarter-over-quarter.
- 34 funds opened new CytomX Therapeutics positions in Q4 2017 and 12 closed out, a net change of +22 holders.
- The largest CytomX Therapeutics buyer in Q4 2017 was Perceptive Advisors, an estimated $22.8M added.
- The largest CytomX Therapeutics seller in Q4 2017 was BVF Inc, an estimated $22.9M sold.
Based on aggregated 13F filings for Q4 2017.